SOS Jelly | An advanced biological remedy against jellyfish stings

Summary
In recent years anomalous proliferations of jellyfish are increasing in all seas: human envenomation by jellyfish toxins produce immediate toxicity (from minutes to few hours), with allergic responses, generally determining local symptoms (dermatitis, oedema and swelling, itching, stiffness, necrosis, pain) or more severe systemic effects. These can also be life threatening and, sometimes, bring to death.
It has been estimated there are 150 million jellyfish stings a year, about 200,000 people are annually stung by jellyfish in the only Florida. $350 million in losses to the Black Sea’s fishing and tourism industries resulted from the invasion of the comb jelly into the Black Sea. Therefore, beyond a public health issue, jellyfish also constitute a threat to tourism.
Sea anemones can kill other fish that touch them; clownfish is therefore immune to the poison, thanks to generation of a biomimetic film on the fish skin. Toxins in the different types of Cnidarian (e.g. medusa and anemones) are similar, as they developed from common ancestors and belong to the same lineage.
The project SOSJelly intends to evaluate the feasibility of the development, manufacturing method, technological transfer and industrial scale-up and to third parties manufacturers, and licensing for commercialization of a completely new biosynthetic molecule or mix of molecules, with bio-mimetic properties, for the first time, able to protect human skin from the jellyfish contact effects.
Furthermore, ABICH laboratory will formulate creams and gel without preservatives at all, suitable for allergic people. At the end of the Phase I, a pre-commercial advanced SOS Jelly “package” (ingredient, formulation, laboratory test, regulation compliance, etc.) will be offered to manufacturers of sunscreen products.
Target market is a high volume and growing market (millions of people, only in Europe); a first entry in Mediterranean market is foreseen (France and Italy, as the main market).
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/728647
Start date: 01-06-2016
End date: 30-11-2016
Total budget - Public funding: 71 429,00 Euro - 50 000,00 Euro
Cordis data

Original description

In recent years anomalous proliferations of jellyfish are increasing in all seas: human envenomation by jellyfish toxins produce immediate toxicity (from minutes to few hours), with allergic responses, generally determining local symptoms (dermatitis, oedema and swelling, itching, stiffness, necrosis, pain) or more severe systemic effects. These can also be life threatening and, sometimes, bring to death.
It has been estimated there are 150 million jellyfish stings a year, about 200,000 people are annually stung by jellyfish in the only Florida. $350 million in losses to the Black Sea’s fishing and tourism industries resulted from the invasion of the comb jelly into the Black Sea. Therefore, beyond a public health issue, jellyfish also constitute a threat to tourism.
Sea anemones can kill other fish that touch them; clownfish is therefore immune to the poison, thanks to generation of a biomimetic film on the fish skin. Toxins in the different types of Cnidarian (e.g. medusa and anemones) are similar, as they developed from common ancestors and belong to the same lineage.
The project SOSJelly intends to evaluate the feasibility of the development, manufacturing method, technological transfer and industrial scale-up and to third parties manufacturers, and licensing for commercialization of a completely new biosynthetic molecule or mix of molecules, with bio-mimetic properties, for the first time, able to protect human skin from the jellyfish contact effects.
Furthermore, ABICH laboratory will formulate creams and gel without preservatives at all, suitable for allergic people. At the end of the Phase I, a pre-commercial advanced SOS Jelly “package” (ingredient, formulation, laboratory test, regulation compliance, etc.) will be offered to manufacturers of sunscreen products.
Target market is a high volume and growing market (millions of people, only in Europe); a first entry in Mediterranean market is foreseen (France and Italy, as the main market).

Status

CLOSED

Call topic

SMEInst-03-2016-2017

Update Date

27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
H2020-EU.2.1.4. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology
H2020-SMEINST-1-2016-2017
SMEInst-03-2016-2017 Dedicated support to biotechnology SMEs closing the gap from lab to market
H2020-SMEINST-2-2016-2017
SMEInst-03-2016-2017 Dedicated support to biotechnology SMEs closing the gap from lab to market
H2020-EU.2.3. INDUSTRIAL LEADERSHIP - Innovation In SMEs
H2020-EU.2.3.1. Mainstreaming SME support, especially through a dedicated instrument
H2020-SMEINST-1-2016-2017
SMEInst-03-2016-2017 Dedicated support to biotechnology SMEs closing the gap from lab to market
H2020-SMEINST-2-2016-2017
SMEInst-03-2016-2017 Dedicated support to biotechnology SMEs closing the gap from lab to market